Cellular and T cell engager Immunotherapy
Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
Sébastien Anguille, n/a
Head of the Division of Hematology of the Antwerp University Hospital
Vaccine and Infectious Disease Institute, University of Antwerp, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital
Edegem, Belgium